1. Mai 2027
FDA PDUFA target action date for AXS-12 (reboxetine), a NDA from Axsome Therapeutics. This is the date by which the FDA is due to act on the application; it can be extended or the decision can come earlier.
FDA-PDUFA-Entscheidungstermine-Kalender